Relay Therapeutics (RLAY) Depreciation and Depletion (2019 - 2026)

Relay Therapeutics (RLAY) has 8 years of Depreciation and Depletion data on file, last reported at $504000.0 in Q1 2026.

• Depreciation and Depletion for Q1 2026 came in at $504000.0, down 58.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.9 million (down 45.94% YoY), and the FY2025 annual result was $3.6 million, down 34.9% from the prior year.
• Depreciation and Depletion eased to $504000.0 in Q1 2026 per RLAY's latest filing, from $599000.0 in the prior quarter.
• Over five years, Depreciation and Depletion peaked at $1.4 million in Q1 2024 and troughed at $504000.0 in Q1 2026.
• A 5-year average of $1.1 million and a median of $1.2 million in 2023 frame the typical range for Depreciation and Depletion.
• The sharpest annual moves came in 2023 and 2026: Depreciation and Depletion soared 39.54% in 2023, then tumbled 58.28% in 2026.
• A 5-year view of Depreciation and Depletion shows it stood at $1.2 million in 2022, then rose by 17.92% to $1.4 million in 2023, then retreated by 2.98% to $1.3 million in 2024, then tumbled by 55.1% to $599000.0 in 2025, then dropped by 15.86% to $504000.0 in 2026.
• Business Quant data shows RLAY's Depreciation and Depletion at $504000.0 in Q1 2026, $599000.0 in Q4 2025, and $748000.0 in Q3 2025.